List view / Grid view
7 December 2015 | By Victoria White
The €100m ENABLE project aims to identify at least three antibacterial lead molecules with promising antibacterial activity, two antibacterial clinical candidate molecules and to enter at least one compound into preclinical and Phase 1 clinical studies...
7 December 2015 | By Victoria White
The collaboration, facilitated by Johnson & Johnson Innovation, aims to develop new cyclophilin inhibitors for neurodegenerative diseases...
7 December 2015 | By Victoria White
Betalutin is the first in a new class of Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and complement current options for the treatment of non-Hodgkin Lymphoma (NHL)...
4 December 2015 | By Victoria White
The researchers made the discovery using mice modified to carry the same mutation as people born without Nav1.7. Their research revealed that people who lack Nav1.7 also produce higher than normal levels of natural opioid peptides...
4 December 2015 | By Victoria White
ICR scientists have discovered Brf2 acts as a ‘master switch’ within cancer cells that seems to override the normal stress response...
4 December 2015 | By Victoria White
By the end of 2015, Baxalta says it expects to employ approximately 500 individuals at the Global Innovation Centre...
3 December 2015 | By Victoria White
Researchers say nanobombs might overcome a biological barrier that has blocked development of agents that work by altering the expression of genes in cancer cells...
3 December 2015 | By Victoria White
Morphotek has teamed up with UW-Madison to investigate the immunosuppressive effects of CA125 on farletuzumab...
3 December 2015 | By Victoria White
Preclinical testing demonstrated that the new antibodies work as a prophylaxis to provide short-term immunity and as a treatment to accelerate recovery...
3 December 2015 | By Victoria White
Using cell cultures of melanoma, researchers showed that these acid ceramidase inhibitors make melanoma cells more prone to be killed...
2 December 2015 | By Victoria White
GBI Research states that the majority of oncology therapeutics are in the early stages of the pipeline, with 2,937 at the Preclinical stage and 1,591 at the discovery stage...
2 December 2015 | By Victoria White
Boehringer Ingelheim and The University of Texas MD Anderson Cancer Centre are to focus on developing new medicines for pancreatic ductal adenocarcinoma...
2 December 2015 | By Victoria White
In preclinical research, the 5B1 antibody has demonstrated high specificity and affinity, and has shown potent cancer cell killing capacity and efficacy in animal models of pancreatic, colon and small cell lung cancers...
1 December 2015 | By Victoria White
The team from the Broad Institute and the McGovern Institute for Brain Research found that mutations in three amino acids dramatically reduced “off-target” cuts...
1 December 2015 | By Victoria White
With Universal Cells’ proprietary gene editing technology, Adaptimmune intends to develop affinity enhanced donor T-cells...
